Promoting Inmune Response

Promoting Inmune Response

 

BRM‘s



This year about 1.3 million Americans will learn they have cancer. Fifteen hundred US citizens will die of cancer every day this year. Although advances in cancer treatments with new drugs (chemotherapy) and techniques (like radiotherapy) have shown great advances in the last 10 years, more than in the last seven decades, a recent report in the Journal of Cancer showed that overall cancer rates and deaths in US have declined only very, very slightly over the past few years. While some experts hail the tiny decreases as signs that the war, on cancer is being won, other have lamented that years of vast expenditures on research into cancer treatment have yield only meager results.

Two of the issues that has had more projection is the advance in cancer Prevention (with the newest techniques of diagnosis) and Nutrition (with diets, vitamins and supplements and Immunotherapy. Traditionally scientists have tackled cancer by screening thousands of compounds in the lab, hoping to stumble over one that kills tumor more efficiently than it kills normal growth. Researchers often test medicines with little real understanding of how they do whatever they do.

The new approach comes from the opposite direction; Understand what�s wrong inside the cancerous cell, then design a medicine that corrects just that. The fundamental difference between cancerous and normal cells lies in the genes. Genetic errors, accumulated over a life time (deficient diets, toxic expositions and pollution) turns good cells into bad ones that escape the normal cycle of life and death. In the past care of patients with cancer required an understanding of three treatment modalities: Surgery, radiation therapy and chemotherapy.

Over the last two decades, medical technology has developed a group of agents whose primary site of action is the immune system. Collectively known as Biological response modifiers (BRMs), these agents now comprise the fourth type of cancer therapy. BRM therapy, also known as immunotherapy, has been widely publicized and patients in a variety of settings are asking about this new treatment modality.

The immune system is an intricate biological infrastructure that distinguishes self (the tissue and organs of the body) from nonself (microorganisms, toxins, transplanted tissues and cancer cells). Failure of the immune system to make this distinction may be responsible for autoimmune diseases (when self is recognized as nonself) and the initiation.

Components of the Immune System.
Though located throughout the body, the components of the Immune system are concentrated in the lymphatic system. By acting as filters, the tissues of the lymphatic system assist in the physical removal of nonself organisms and cells. Lymphatic tissues include the tonsils and adenoids, the thymus gland, the spleen, the lymph nodes (such as those in the neck, the axilla, and the inguinal area), and the lymphatic vessels and fluids. Parts of the lymphatic system are included in the bone marrow and areas of the liver.
Cell Mediated Immunity.
A major component of the immune system is the White blood cell (WBC). There are three major WBC types, granulocytes, lymphocytes and monocytes. Lymphocytes and Monocytes are involved in cell mediated immunity. T lymphocytes (or T Cells) are specific in action. There are many subtypes of T Lymphocytes, each of which will recognize only one type of nonself cell. These include Killer T cells, Helper T cells, Suppressor T cells and Memory T cells.
Three other classes of WBC comprise the nonspecific component of cell mediated immunity.
Polymorphonuclear granulocytes (PMNs) there are four subtypes in this group neutrophils (most common PMN), basophils, eosinophils and mast cells. Also called �polys� PMNs digest and destroy invading microorganisms, specially bacteria. They are the body�s first line of defense against infection.

Natural Killer cells (NK cells) these cells have the ability to recognize and destroy cancer cells and virus-infected cells.

Monocytes they are mononuclear phagocytes that are precursors to tissue macrophages. When mature, macrophages trap nonself cells or damaged self cells and then digest them. And play a role in the specific immunity by preparing or processing the antigen for recognition by the immune system.

Humoral Immunity. Involves the activation of two groups of proteins that play a key role in the body�s resistance to infectious diseases. These proteins help trap and kill nonself cells before they have invaded a self cell.

Immunoglobulins (antibodies). Produced by B lymphocytes, immunoglobulins have the capacity to bind with nonself antigens to form the antigen- antibody complex.

There are five classes of Immunoglobulins. Each class plays a different role in binding to a specific nonself antigen.
Cytokines. Cytokines are immune system proteins known as Biological Response Modifiers that serve two essential functions: Cytokines orchestrate the interplay between the Cellular and Humoral components of the immune system and augment the immune response.
There are two types of Cytokines:

Monokines and Lymphokines :
  • - Monokines are produced by tissue macrophages and include alfa-Interferon (aJFN), beta Interferon (bIFN), interleukin-1 (IL-I), tumor necrosis factor (TNF), and several of the colony-stimulating factors (CSFs).
  • - Lymphokines. Are soluble proteins that are released from activated lymphocytes particularly from T and NK cells). Some of the known lymphokines are gamma interferon (G-IFN), ILs-2, -3, -4, -5 and -6, granulocyte- macrophage colony-stimulating factor (GM-CSF) and Lymphotoxyn.
BRM‘s Biological Response Modifier therapy is the combined product of several disciplines: Biology, Genetics, immunology and Pharmacology, Medicine and Nursing to mention a few.

The BRMs have the following therapeutic effect:
  • - Regulation and /or augmentation of the immuneresponse.
  • - Cytotoxic or cytostatic activity directed toward cancer cells.
  • - Inhibition of metastasis (cancer spreading to other sites), differentiation or maturation.
  • - Immune regulation and immune restoration.
  • - Improved tolerance of normal cells to anticancer therapy.
  • - Direct antitumoral effects.

THE BENEFITS OF EUROPEAN MISTLETOE/ISCADOR

Viscum album is a European type of mistletoe that has been used since the turn of the century in Switzerland and Germany to treat cancer and other diseases.

Scientific information has revealed that this herbal extract helps fight cancer in two basic ways. It works as immunoregulator and has anti-tumoral properties.

It causes the cancer cell to change back into a more differentiated form, thus promoting its regression.

  • - Regulation and/or augmentation of the immune response.
  • - Cytotoxic or cytostatic activity directed toward cancer cells.
  • - Inhibition of metastasis, differentiation or maturation.
  • - Immune regulation and immune restoration.
  • - Improved tolerance of normal cells to anticancer therapy.
  • - Direct antitumoral effects.

Iscador

TRANSFER FACTOR



Transfer factors are immune molecules that cause antigen-specific cell-mediated immunity, primarily delayed hypersensitivity and the production of Lymphokines (Lymphokines are a subset of cytokines that are produced by a type of immune cell known as a lymphocyte. They are protein mediators typically produced by T cells to direct the immune system response by signaling between its cells. Lymphokines have many roles, including the attraction of other immune cells, including macrophages and other lymphocytes, to an infected site and their subsequent activation to prepare them to mount an immune response. Circulating lymphocytes can detect a very small concentration of lymphokine and then move up the concentration gradient towards where the immune response is required. Lymphokines aid B cells to produce antibodies.), as well as binding to the antigens themselves. They have a molecular weight of approximately 5000 Daltons and are composed entirely of amino acids.

What is Transfer Factor
Many of you will have heard of colostrum which is the milk produced in the first few days after childbirth. Colostrum contains a potent array of immune factors which can be passed from mother to child, and is available in supplement form in health food stores from bovine sources. The principle immune factor in colostrum is a group of molecules called �Transfer Factor�. Transfer factor was first discovered in 1949 and can also be derived from egg yolk protein and human white blood cells. Transfer Factor supplements are concentrated sources of Transfer Factor in doses much higher than is achieved by taking colostrum supplements.

What effects does Transfer Factor have on people?

Transfer Factor is an immune system rebalancer which:
  • Improves immune function and reduces the burden of chronic infections.
  • Down regulates auto-immunity.
  • Down regulates allergic response (e.g. foods, molds, dust, pollen, cats, etc.).
What medical conditions is Transfer Factor beneficial for?
  • - Allergic conditions (e.g. eczema, psoriasis, asthma, hives, hay fever, food allergies, etc.)
  • - Autism Spectrum
  • - Auto-immune conditions (e.g. SLE, MS, etc.)
  • - Cancer
  • - CFS/FM
  • - Chronic infections (HIV, viral hepatitis, etc.)
  • - Recurrent infections (e.g. ear infections, UTI�s, etc.)

AUTOLOGOUS VACCINE

Certain microorganisms in human blood, body fluids, and tissues which were highly "pleomorphic", can appear in various developmental stages and in diverse forms by maintaining their characteristics. When they host terrain deteriorates, they seem to transform from primitive structures into higher cyclogenetic structures. They appear to become pathogenic and may be causative or co-factors in the development of malignancies, various chronic degenerative diseases and immune disorders. They induce malignant changes in a high percentage of cell cultures or when transmitted into an animal host organism.

Scientists have observed that higher cyclogenetic structures can be reversed by the administration of lower cyclogenetic structures.

These microorganisms are stainable, cell wall deficient, virus-like, and pleomorphic. Since the early 1950‘s, German researchers developed cancer vaccines in the laboratories. They regularly and meticulously monitored the impact of these vaccines and on the general treatment on the patient by also examining live and modified-gram stained blood under the darkfield microscope before, during, and after treatment. Field tests confirmed the results and showed changes of microbial forms when the blood pH changed.

Among these researchers was Dr. Franz Gerlach, Professor of the University of Vienna, who also worked at the Pasteur Institute in Paris. Dr. Gerlach was well known to cancerologists all over the world for his research on mycoplasmas and cancer.

The Autologous vaccine has proven most effective. It is prepared from the patient�s own blood which represents his/her unique internal microbial environment. The vaccine is customized to fulfill individual immunobiological needs. The preparation follows a procedure that favors the development of antigenic peptides and other immunogenic compounds which act in concert to restore the body�s natural defense mechanisms.

Clinical research suggests that:
  1. The vaccine stimulates the formation and activation of T-helper cells, macrophages, and natural killer cells.
  2. As an antigen fraction of autologous mycoplasmas and mycoplasma-like organisms, it binds mycoplasma-specific antigens by cluster formation.
  3. It exposes the cancer cells to the immune system by degrading their protective mechanisms.

Autologous Vaccines

SENSITIZED LIMPHOCYTES

Studies have determined that products of activated human lymphocytes alter human monocyte function. Supernatants from sensitized human lymphocytes stimulated by specific antigens were cultured with monolayers of human monocytes. Such monocytes exhibited enhanced adherence to their culture vessels and increased glucose carbon-1 oxidation after 2-3 days of incubation. The substance responsible for these effects was found to elute in a same fraction as the migration inhibitory factor.

This tells us that human monocyte functions can be altered by products of activated lymphocytes.

This may be one of the early steps in the lymphocyte-macrophage interaction in cellular immunity directed against certain microorganisms or tumors. This also proves useful in assessing monocyte functions face to face against cellular immunity in various disease states, particularly if used in conjunction with other measures of monocyte responsiveness to lymphocyte mediators (such as their inhibition of migration) and with the methods for assessing lymphocyte function. This helps us to determine whether lymphocyte mediators alter the phagocytic or bactericidal capacities of human monocytes or affect certain of their membrane receptors such as those for IgG or C8. Such information on the various aspects of monocyte and. lymphocyte function defines the underlying defects in immunodeficiency states of unknown etiology.

 

Sensitized Lymphocytes